Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc. (NASDAQ:NVAX ) Jefferies 2024 Global Healthcare Conference June 6, 2024 12:30 PM ET Company Participants John Jacobs - President and CEO Filip Dubovsky - Chief Development Officer Jim Kelly - CFO Conference Call Participants Roger Song - Jefferies Roger Song All right. Good afternoon, everyone.

Novavax, Inc. (NVAX) Jefferies 2024 Global Healthcare Conference (Transcript)

Novavax NASDAQ: NVAX is a drug and vaccine manufacturer in the healthcare sector known for its efforts in the COVID-19 vaccine market. Novavax's stock price has experienced a remarkable surge recently, attracting significant attention from investors and Novavax's analyst community.

Novavax Stock's Recent Surge and Future Potential

Vaccine maker Novavax (NASDAQ: NVAX ) saw its shares jump 18% on June 5 and another 20% in pre-market trade this morning. NVAX stock is up over 300% year-to-date.

Is a Giant Short Squeeze Brewing in Novavax (NVAX) Stock?

Novavax stock zipped to a nearly two-year high Thursday after the FDA set a potential approval date for its Covid vaccine in April.

Novavax, With A 369% Gain, Tears Ahead Again On Key FDA Move

Novavax (NASDAQ: NVAX) stock price has gone parabolic this year, making it one of the best-performing companies in New York. It has soared by over 335% in 2024 and by almost 500% from its lowest level this year.

My Novavax stock price forecast was correct: what next now?

Moderna

Pfizer

WASHINGTON — Government advisers Wednesday said it's time to update the recipe for the COVID-19 vaccines Americans will receive in the fall — targeting a version of the ever-evolving coronavirus called JN.1.

FDA advisers urge targeting JN.1 strain in fall's COVID vaccines

Novavax (NASDAQ: NVAX ) is on a recovery trek after collapsing in late 2021. Recently, management said that its latest vaccine version addressing newer Covid-19 subvariants is more effective than older injections.

Why Is Novavax (NVAX) Stock Up 20% Today?

An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.

FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains

Altair Engineering

CrowdStrike

Growth stocks can be millionaire-makers and the same ideas can be destroyers of wealth. The difference between wealth creation and erosion is the timing of exposure.

Growth Stocks to Avoid Like the Plague: 3 Overpriced Picks Primed to Plummet

GAITHERSBURG, Md. , May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.

Novavax to Participate in 2024 Jefferies Global Healthcare Conference

Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started manufacturing that targets a variant that was dominant earlier this year, the company said.

Novavax awaits FDA decision on whether its next COVID shot can be offered in US

BioNTech SE

H5N1 bird flu was detected this week in Michigan and Australia. It's the first detection in humans since March, when news of an outbreak in cattle emerged.

Why Vaccine Stocks Rallied This Week

Gilead Sciences

Thermo Fisher Scientific

While it tends to fly under the radar for many people, the biotech industry has seen a resurgence in investor interest over the last couple of years. While there could be several reasons for this, such as the COVID-19 pandemic bringing the value of biotechnology to the forefront or even the expansion of education in the biosciences, the fact remains – biotech is getting more attention than ever before.

3 Biotech Stocks to Buy Now: May 2024

Inovio Pharmaceuticals

Novavax just signed a lucrative agreement with a biotech giant. Inovio Pharmaceuticals is inching closer to launching its leading candidate.

Better Buy: Inovio Pharmaceuticals vs. Novavax

Novavax stock surged after the company announced a partnership with pharma giant Sanofi. The biotech stock has spent the past few years in the doldrums after sales of its coronavirus vaccine disappointed investors.

3 Things You Need to Know If You Buy Novavax Today

Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company?

Why Novavax (NVAX) Stock Price Appreciated 14% on Monday

Robinhood

Workhorse Group

GameStop (NYSE: GME ) and AMC (NYSE: AMC ) meme stocks rose substantially last week, gaining over 70%. The return of ‘Roaring Kitty', prominent investor Keith Gill, has traders wondering which meme stocks to buy next.

Roaring Kitty's Rally Cry: 3 Meme Stocks to Pounce On Now

Sanofi

Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's board, after the COVID-19 vaccine maker struck a licensing deal with Sanofi.

Shah Capital ends campaign against Novavax board after Sanofi deal

Novavax recently entered into a lucrative, multitiered deal with Sanofi. The agreement helps improve Novavax's prospects.

This Stock Just More Than Doubled in 1 Day: Is It a Buy?

Novavax reached a deal with Sanofi recently which sent the stock soaring. The company now expects to generate up to $1.2 billion in revenue this year.

Is Novavax Stock a Buy?

The stock price of Novavax (NASDAQ: NVAX), a Covid-19 vaccine developer, trades at $13 per share, about 96% below its peak level of $320 seen in February 2021. NVAX stock was trading at around $51 in early June 2022, just before the Fed started increasing rates, and is now 75% below that level, compared to a substantial 40% gain for the S&P 500 during this period.

Up 3x In A Week Will Novavax Stock Continue To See Higher Levels?

Moderna's sales soared into the billions as it conquered the coronavirus vaccine market -- and today the company promises to deliver many new products in the near term. Novavax struggled in recent times, but it's alliance with a vaccine market giant could turn things around.

Could Novavax Become the Next Moderna?

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The settlement provides for a fund of $47,000,000 to benefit class members.

Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement

Shopify

Target

The S&P 500 is on the longest streak since February, partly buoyed by stocks with analyst upgrades. The Dow Jones Industrial Average is also increasing amid mixed economic signals, as consumer sentiment dropped to a six-month low due to heightened short-term inflation expectations.

Analyst Upgrades: 3 Stocks Getting the Nod From Pros Last Week

The vaccine developer's shares got a hefty pop on the announcement of a collaboration deal. In the mind of one pundit tracking the stock, however, this means the shares are now fairly valued, and might even fall in price.

News for Novavax Stock (NVAX)